Couples at risk for having children with a genetic disorder are frequently using Preimplantation Genetic Testing for monogenic disorders (PGT-M) to decrease the risk of having an affected child. The use of PGT-M requires undergoing in vitro fertilization (IVF) treatment even though a majority of PGT-M couples do not suffer from infertility, and thus many assume their lack of an infertility diagnosis entails higher success rates than those using IVF for infertility. However, due to the necessary exclusion of affected embryos, it is not uncommon for couples utilizing PGT-M to have fewer euploid embryos available for transfer than their infertile IVF counterparts 1 . As a result, predicting outcomes for fertile patients who use PGT-M is often challenging, particularly when counseling the couple on the number of cycles needed to achieve a pregnancy. While a number of prior studies have looked at outcome data for PGT-M cycles, few have included concurrent pre-implantation genetic testing for aneuploidy (PGT-A). 2, 3 This
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Design:
Retrospective cohort analysis
Materials and Methods:
The study included infertile patients who underwent IVF with PGT-A and patients presenting at 
Conclusions:
Due to the growth of expanded carrier screening panels and increased utilization and appreciation for personalized medicine, PGT-M will likely become another routine aspect of treatment for the modern IVF patient. Our study shows that patients who sought IVF solely for the purposes of PGT-M had comparable IVF and pregnancy outcomes to their counterparts who underwent similar procedures. However, these patients should be informed that it may require approximately 20% more VOR cycles to reach their goals of obtaining embryos that are both euploid and unaffected. Couples interested in utilizing IVF with PGT-M can thus be counseled that while they may require more VOR cycles, the published IVF with PGT-A success rates for their age bracket are representative of their own probability of success and that ultimately the most important factor influencing chance of pregnancy is the transfer of a euploid embryo. With more targeted counseling, clinicians can better equip couples for the emotional and financial undertakings of IVF with PGT-M with PGT-A and better guide them to realizing their goals of conceiving a healthy child. 
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